Abstract Background Hormone Therapy (HT) reduces the risk of breast cancer recurrence
and mortality in women with breast cancer. Despite these clinical benefits, rates of HT non …

Purpose In the past decade, there has been an increase in the development and use of oral
anti-cancer medications (OAMs), especially for breast cancer–the most prevalent cancer in …

Purpose Many patients with hormone receptor–positive (HR+) breast cancer do not adhere
to endocrine therapy (ET), and treatment-related side effects are often discussed by …

Purpose Adjuvant endocrine therapy (AET) significantly reduces the risk of breast cancer
recurrence and mortality in women with hormone receptor (HR+) breast cancer. Despite the …

Medication adherence is directly associated with health outcomes. Adherence has been
reviewed extensively; however, most studies provide a narrow scope of the problem …

To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related
quality of life (QoL), subjective well-being and distress prevalence in Breast Cancer (BC) …

Introduction Many women in rural Ethiopia do not receive adjuvant therapy following breast
cancer surgery despite the majority being diagnosed with estrogen-receptor-positive breast …

Rationale To identify high‐risk survivors in order to provide appropriate care. Purpose To
analyse the quality of life (QOL) of cancer survivors using an instrument designed …

Objective Non‐adherence to adjuvant endocrine therapy (AET) for breast cancer leads to
increased recurrence and mortality risk and healthcare costs. Evidence on feasible, effective …

Purpose Despite life-saving potential, many women struggle to adhere to adjuvant
endocrine therapy (AET) for their breast cancer (BCa). Prior research has demonstrated that …